Medicamen Organics Ltd IPO

Medicamen Organics Limited is engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer. The Company markets its product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. Further, the Company is also strategically focusing on establishing a direct presence in international market for an instance in fiscal 2023, it has directly exported its product in Burundi. The Company has a track record of operating B2B model which covers contract manufacturing model. Its products are marketed across India as well as African, Commonwealth of Independent States (CIS) region and south East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by its third-party distributor.

Open Demat Account


Medicamen Organics Ltd IPO Details


Total Shares OfferedOffer to PublicRetail Max (Shares)Pre Issue Promoters HoldingExchangeIssue size
31 LTBA10.28 L66.9 LNSE₹ 10.54 Cr
IPO Open DateClose DateLot SizeMin InvestmentIssue TypeListing Date
21 Jun, 2425 Jun, 244000 ₹ 1,28,000 Book Building - SME28 Jun, 24

Medicamen Organics Ltd IPO Dates

  • 21 Jun 2024

    Opening date

  • 25 Jun 2024

    Closing date

  • 26 Jun 2024

    Basis of

  • 26 Jun 2024

    Initiation of

  • 27 Jun 2024

    Credit of

  • 28 Jun 2024

    Listing date


SectorPharmaceuticals - Indian - Formulations
Sub SectorNA
Issue TypeBook Building - SME

Subscription Status

*Values are in Lakhs

Investor TypeSubscription TimesShares Offered*Shares Bid*

Subscription Status

Investor Type






*Values are in Lakhs

Medicamen Organics Ltd Financial Status

Income Statement

Balance Sheet

Particulars (in Rs. Crores)FY23FY22FY21
Revenue from operations4.112.070.94
Total Assets27.3720.9315.49
Share Capital8.606.006.00
Total Borrowings9.679.049.16
Operating Activities (Net Cash)3.121.680.77
Investing Activities (Net Cash)-
Financing Activities (Net Cash)9.679.049.16
Net Cashflow0.550.530.44

Particulars (in Rs. Crores)

Revenue from operations



Total Assets

Share Capital

Total Borrowings

Operating Activities (Net Cash)

Investing Activities (Net Cash)

Financing Activities (Net Cash)

Net Cashflow

About Medicamen Organics Ltd

Medicamen Organics Limited was incorporated on March 15, 1995 as `Panchdeep Pharmaceuticals Limited', a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of the Company was changed to `Medicamen Organics Limited' and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi.

According to a recent EY FICCI report, there has been growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the US$ 1 trillion mark in 2024. India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving into a thriving industry growing at a CAGR of 9.43% in the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most pharmaceutical manufacturing facilities that comply with the US Food and Drug Administration (USFDA) and has 500 API producers that makeup around 8% of the worldwide API market. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with the potential to steer industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the pharmacy of the world due to the low cost and high quality of its medicines.

Peer Comparison:

  • Brooks Laboratories Ltd
  • Cian Healthcare Ltd
  • Zenotech Laboratories Ltd

Medicamen Organics Ltd IPO Key Points


  • Experienced Promoters and Management Team.
  • Long standing relationships with customers.
  • Efficient operational team.
  • Consistent financial performance.


  • The Company, its Directors and its Promoters are party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make it liable to liabilities/penalties and may adversely affect its reputation, business and financial status.
  • The company requires a number of approvals, licenses, registrations and permits in the ordinary course of its business and any failures or delay in obtaining the same in a timely manner may adversely affect its operations.
  • Its business activities are exposed to fluctuations in the prices of raw materials.


  • Improve global presence.
  • Maintaining edge over competitors.
  • Expansion Plan.
  • Customer Satisfaction.
  • Experienced Promoters and Management Team.
  • Long standing relationships with customers.
  • Efficient operational team.
  • Consistent financial performance.

How To Apply for Medicamen Organics Ltd Online?

Step 1:

Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

Get your FAQs right

Medicamen Organics Ltd's IPO offers shares for up to ₹ 0 L It begins on Jun 21, 2024 and ends on Jun 25, 2024.

The price of Medicamen Organics Ltd IPO ranges between ₹32 to ₹34 per share.

The Medicamen Organics Ltd IPO opens on Jun 21, 2024 and closes on Jun 25, 2024.

The allotment for the Medicamen Organics Ltd IPO will be finalised on Jun 26, 2024. The shares will be listed on BSE and NSE on Jun 28, 2024.

The minimum lot size for Medicamen Organics Ltd IPO is 4000 shares, priced between ₹32 to ₹34 per share.

The GMP (Grey Market Premium) of Medicamen Organics Ltd IPO fluctuates based on market demand and sentiment.

To check the allotment status of Medicamen Organics Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

The Medicamen Organics Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Jun 21, 2024, and closes on Jun 25, 2024. The allotment is finalised on Jun 26, 2024.

To apply for the Medicamen Organics Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.